DILUENT AND METHOD FOR DETERMINATION OF TOTAL CALCIUM

Abstract: Diluents and methodologies for determining the concentration of total calcium in a clinical sample (e.g. whole blood, sera plasma urine cerebro spinal fluid) containing protein-bound calcium are disclosed. Methodologies include the steps of: (a) admixing the sample with a diluent, the diluent including effective amounts of a pH buffer and at least two agents capable of complexing free calcium in the sample, where the agent-calcium complex association constants ("log K" in base 10) each have a range from about 1.5 to about 7.0; and (b) contacting an aliquot of the diluted sample with a calcium-specific ion selective electrode. The response of the calcium-specific ion selective electrode is an indication of the concentration of total calcium in the sample.

Description: DILUENT AND METHOD FOR DETERMINATION OF TOTAL CALCIUM FIELD OF THE INVENTION The present invention is related to indirect potentiometric methodologies and diluents and particularly to a diluent useful in the indirect potentiometric deter¬ mination of total calcium in clinical samples of bodily fluids. BACKGROUND OF THE INVENTION Calcium, the fifth most abundant element in the human body, plays an important physiological role and is essential for both the functional integrity of the nervous and muscular systems as well as normal cardiac function. Calcium is also one of the factors that operates in the mechanisms involved in the coagulation of the blood. More than 90% of the calcium in the human body is in the skeleton as calcium phosphate and calcium carbonate — the remainder of calcium is present in plasma. Plasma calcium levels vary from between about 9.0 and about 11.Omg/lOOml. On average, about 46% is bound to protein; slightly more is free and ionized; and the remainder is freely defusable but complexed and ionized. Total calcium, or "CaT", is the combined value of bound calcium ("CaB") free calcium ( "CaF" or "Ca ++ " ) and protein complexed calcium ("CaP"), or: CaT = CaB + CaF + CaP CaF is generally accepted as being the physiologically active form of calcium in sera. Potentiometric sensors in the form of ion selective electrodes are useful in the determination of CaF. Ion selective electrode technology involves the use of a reference electrode and an ion selective electrode ("ISE") separated by a membrane which are simultaneously immersed in a sample of a solution containing the desired ion. This simultaneous immersion leads to a potential across the membrane between the electrodes, which potential is proportional to the presence of the desired ion. Most often the investigator desires to only measure the concentration of one ion out of many different ions in solution. Thus, the composition of the ion selective electrode ISE must be capable of transporting the desired ion across the membrane in preference to all other ions which may be present. Two methodologies are associated with ISE technology: direct, where the sample is analyzed directly; and indirect, where the sample is diluted prior to analysis. Conventional calcium ISE's only measure the free form of calcium. Accordingly, calcium indirect ISE method¬ ologies employ diluents to displace the protein bound to calcium in an attempt to obtain an accurate reading of free calcium. Such conventional methodologies typically make use of strongly acidic diluents prior to ISE measurement in order to denature proteins bound to the calcium, that is, to displace or, "release", the bound calcium' 1 '. However, some ions, such as citrate (normally present in human sera at a level of about 0.1 mmol/L but during blood transfusions can be present in levels up to about 5 mmol/L) , remain effective in binding calcium even under such acidic conditions* 2 '. Additionally, certain calcium ionophores will not function properly under such acidic conditions. Other methodologies have been described for releasing bound calcium^)* (4 )» ( 5 ) , ( 6 ) . ^ _± of the preceding references of this paragraph are incorporated herein by reference. Because of the problems associated with denaturing proteins bound to calcium in clinical samples, a diluent that does not rely upon denaturation and that does not utilize conditions which have an adverse affect upon the calcium ISE, as well as analytical methodologies employing such diluents, are desirable and would be of great value in the determination of total calcium in a clinical sample. SUMMARY OF THE INVENTION The present invention satisfies these requirements. The invention discloses diluents and methods for determining the concentration of total calcium in a clinical sample containing protein-bound calcium, the method including the steps of: (a) admixing the sample with a diluent having effective amounts of a pH buffer and at least two agents capable of complexing free calcium in the sample, where the resultant agent-calcium complex association constants ("log K" in base 10 ) each have a range from about 1.5 to about 7.0; and (b) contacting an aliquot of the diluted sample with a calcium-specific ion selective electrode. The response of the calcium-specific ion selective electrode is an indication of the concentration of total calcium in the sample. Preferably, only two complexing agents are used; most preferably these are dibasic phosphate (HPO^) and citrate ( (HOJC β H^C^^ ). In a particular embodiment, the pH buffer in the diluent can be a phosphoric acid comprising approximately equal molar amounts of monobasic phosphate (H2P0 4 ) and dibasic phosphate (HP0 4 ), whereby the pH of the diluent is about 7.0. Most preferably, the pH buffer is the above-described phosphoric acid in that the dibasic phosphate portion thereof also serves as one of the complexing agents. The pH of the diluent is preferably within the range of about pH 5.0 to about pH 8.5; most preferably, the pH of the diluent is about pH 7.0. The concentration of the pH buffer in the diluent is at least about 0.1 mole per liter and the concentration of the complexing agents in the diluent are both at least about 0.002 moles per liter. The diluent can further comprise other optional ingredients such as preservatives and surfactants. The volume to volume ratio of the clinical sample to the diluent is between about 1:10 and about 1:40, and most preferably this volume to volume ratio is about 1:20. Because the diluent αoes not include harsh compounds to denature proteins bound to the calcium, the diluent can be used in association with conventional and commercially available calcium-specific ion selective electrodes. DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT The diluent for measuring total calcium in a clinical sample includes therein effective amounts of at least two agents capable of complexing free calcium in the clinical sample. As used herein, the term "complexing agent" is synonomous with "metal ion buffer". In order to be effective, the resultant agent-calcium complex association constant ("log K" in base 10) has a range of from about 1.5 to about 7.0; most preferably, this range is from about 2.0 to about 4.0. Association constants can be derived from the stability constant ("K") of the complexing agent; the stability constants for a variety of such agents can be readily obtained from published sources. See, for example, Sillen & Martell, Stability Constants Special Publication No. 17 London: The Chemical Society, Burlington House, London, England (1964), and Sillen & Martell, Stability Constants, Supplement No. 1 Special Publication No. 25 London : The Chemical Society, Burlington House, London England (1971), which are incorporated herein by reterence. For example, measured association constant for calcium-dibasic phosphate is 2.74; a measured association constant for calcium-citrate is 3.60. Dilution of a clinical sample, e.g., serum, plasma, whole blood, urine, cerebro spinal fluid, with a diluent including therein at least two agents capable of complexing free calcium, equilabrates the protein and other clinical sample compounds bound to the calcium (collectively "CaP") and the agents bound to the calcium ("CaA" and "CaA 1 ") as follows: Ca ++ + A CaA Ca ++ + A' CaA' Ca ++ + P CaP For convenience, charge symbols for A, A' and P are not included. Under the above criteria, total calcium concentration of the diluted sample for two complexing agents can be defined as: [Ca ++ ] + [CaA] + [CaA' ] + [CaP]. Accordingly, at equilibrium, the mole fraction ( "R" ) of the free calcium ion can be expressed as follows: R = fCa÷÷] ;Ca 1 + ICaA) + [CaA 1 I + |CaP| (1) It is to be understood that additional agents can be utilized such that each additional agent (e.g. CaA' ' ) is similarly represented in Equation 1. Equation (1) reduces to ι R = — CaA CaA' CaP 1 + [Ca Ca [Ca ( 2 ) By choosing agents that satisfy the relationship: ICaAl + [CaA 1 ] + >> [CaPI ICa " " " ] [Ca ++ ] *" [Ca ++ ] (3) Equation 2 reduces to R = , , ICaAl , [CaA 1 ] [Ca÷÷l [Ca"] •" < 3 *> In effect, the agents capable of complexing with free calcium are used to mediate or "control" the mole fraction of free calcium such that the amount of protein-bound calcium becomes inconsequential, as indicated in Equations 3 and 3a. R can be expressed as a percentage of free calcium, i.e., R x 100%, and [100% - (R x 100%)] is defined as the value of the total mole percentages of the agent-calcium complexes, assuming that Equation 3 is satisfied. It is useful to first determine a value for one of the agent- calcium complexes such that the other agent-calcium complex(e has that same value, such that f Ca j. = tC. A^| . ICa " * " * " ] [Ca+÷] However, these values need not be equal; the critical requirement is that Equation 3 is satisfied when the values for the agent-calcium complexes are inserted into Equation 3. As such, less complexing agent can be added to the diluent than the amount actually calculated as long as the lesser amount would continue to satisfy Equation J. Additionally, it is useful to obtain values for such that when incorporated into relatively small value, the proviso being that if R has too small a value, the calcium concentration of the sample can be difficult to measure with a calcium specific ion selective electrode and if R has too great a value, the agents become ineffective in maintaining a constant mole fraction of free calcium. The selection of the range of R values is directly related to the volume to volume ratio of the sample to the diluent. For a 1:20 dilution ratio, R is preferably within the range of from about 0.009 to about 0.03, more preferably within the range of from about .01 to about .02, and most preferably about .012. As the dilution ratio decreases, the value range for R will decrease, and as the dilution ratio increases, the value range for R will increase. Thus, for a dilution ratio of 1:10, R is preferably within the range of from about .0025 to about .025; for a dilution ratio of 1:40, R is preferably within the range of from about .01 to about 0.10. For a 1:20 dilution ratio, and utilizing a most preferred value for R of .012, Equation 2 can be expressed as follows: • ° 12 = . , ICaAl , [CaA 1 ] , [CaPT [Ca"] [Ca " H [Ca " H As previously noted, Equation 2 can be rewritten as Equation 3a when Equation 3 is satisfied. For most clinical samples, it is laborious to determine a value for £a L because Ca " ^] all of the stability constants for all pro :eins and other compounds that bind to calcium in the sample are tedious and/or difficult to determine. However, because the complexing agents are used to control the mole fraction of free calcium, a value for [ | can, for practical purposes, have an assigned approximation value of less than or equal to 1.0. With respect to serum, this value can be empirically estimated using Human Serum Albumin, which is the dominant protein species in serum. Because Human Serum Albumin ("HSA") is the dominant HSA as a concentrat on o approx mate y 0.6 mmole/L. Assuming a 1:20 dilution ratio, and using the association constant model for the calcium - complex in human serum set forth in Fogh-Anderson, N. "Albumin/calcium association at different pH, as d termined c.^ potentiometry" Ciin. Chem. 2^:2122-2126 (1977), JCaHSAi = 0-3 ICa " " " ] Accordingly, when I aAl + ICaA_i » o. 3s [Ca"] ICa"] Equation 3a is utilized to determine the concentration of the agents to be added to the diluent. Assuming R to be equal to .012, and further assuming that l Cft U = ISaAjJ- ICa^l [Ca " " " ] then 0.012 = ! + 2x) 0.012 + .012(2x) = 1 012(2x) = .988 x = 41 Accordingly, ICaAl CaA' ICa ++ , = 41 I Lα These values satisfy Equation 3 (82 » 0.3) . Because the value "82" is much greater than 0.3, it is possible to use less of each agent or less of one agent whereby Equation 3 is still satisfied. From a commercial standpoint, this is of beneficial value in that for a particularly strong calcium complexing agent, that is, one having a stability constant indicative of a strong calcium complexing agent, less of the agent can be used without compromising the importance thereof in the diluent. To determine a useful concentration of the agents ([A] and [A 1 ]), the stability constants (K) are utilized as follows: κ = [CaAI [Ca x [A] K x [A| = CaAI [Ca" ICaAl ICa K As set forth above, for | CflA . = 41, then: 1*1 - The association constant of the agent-calcium complex is preferably within the range of about 1.5 to about 7.0, with a most preferred range of from about 2.0 to about 4.0. Calcium-dibasic phosphate, at pH 7.0, has a measured association constant of 2.74; calcium-citrate, at pH 7.0, has a measured association constant of 3.60. Accordingly 41 [ Dibasic phosphate ] = — ~7 ~ °*075M 10' 41 [ Citrate ] = ,3 • 3.6 e0n = .010M 10' The molar value for dibasic phosphate represents only one- half of the necessary amount of phosphoric acid that must be added to the diluent in that at pH 7.0, the other form of phosphoric acid is monobasic phosphate. Therefore, at pH 7.0, 0.15M phosphoric acid is utilized because of this factor. Additionally, and for the reasons noted above, less citrate can be used under these conditions, for example, .005M (5 mmol) . Examples of suitable agents that satisfy the agent- calcium complex association constant requirements include: dicarboxylic acids; tricarboxylic acids; iminodiacetic acids; sulfonic acids; and organophosphoric acids. Specific agents include: aspartic acid; gluconic acid; succinic acid; oxaloacetic acid; propane-l,2,3-tricarboxylic acid; citric acid; iminodiacetic acid; N-methyliminodiacetic acid; 4,5-dihydroxy-l,3-benzenedisulfonic acid; glycerol-2- phosphate, disodium salt; N-( 2-hydroxycyclohexyl) iminodiacetic acid; nitrilotriaretic acid; N'-(2- hydroxyethyl) ethylenediamine-N,N,N'-triacetic acid; ethylenediamine-N,N-diacetic acid; 8-hydroxyquinoline-5- sulfonic acid; and phosphoric acid. The pH buffer is chosen such that the pH of the diluent is within the range of about pH 5.0 to about pH 8.5. Preferably, the pH of the diluent is about 7.0. Combinations of pH buffers can be utilized to satisfy these requirements. The pH buffer can comprise at least one of the following: acetic acid; 2-(N-morpholino)ethanesulfonic acid; 3-(N-morpholino) propanesulfonic acid; N-2- hydroxyethyl piperazine-N'-2-ethanesulfonic acid; phosphoric acid; N-[tris-(hydroxymethyl)methyl]glycine; diethynol amine; dimethylamine; phosphoric acid; and the alkyl amines. Most preferably the pH buffer is the aforementioned phosphoric acid. The pH buffer has a concentration in the diluent of at least about 0.1 mole per liter, more preferably a concentration in the diluent of between about 0.1 mole per liter and about 0.4 mole per liter, and most preferably a concentration in the diluent of about 0.15 mole per liter. Other ingredients can be added to the diluent that do not affect the diluent and which are used in association with the pH buffer to balance the charge thereof. For example, when phosphoric acid is used as a pH buffer, it is useful to include in the diluent a "counter cation", i.e. an ingredient to balance the anionic charge of the phosphoric acid. For phosphoric acid, a suitable counter cation is tris-(hydroxymethyl)aminomethane (hereinafter "TRIS"). The diluent can also include therein a surfactant, the preferred surfactant being non-cationic, and more preferably 2,4,7,9-tetramethyl-5-decyn-4,7-diol. The foregoing surfactant is commercially available under the brand-name Surfynol 104™ (Air Products, Allentown, PA). A preservative can also be added to the diluent, such as, for example, phenoxyethanol. An embodiment of the presently claimed diluent would include the following: Total Calcium Diluent Ingredient Concentration TRIS 0.30 mole per liter phosphoric acid 0.15 mole per liter citrate (citric acid) 5 milimole per liter 2,4,7, 9-tetramethyl-5-decyn- 4,7, diol 0.02 per cent by weight phenoxyethanol 0.02 per cent by weight pH of diluent 7.0 It is to be understood that the foregoing description or an embodiment of the diluent is not to be construed as an indication that the complexing agents are limited to dibasic phosphate and citrate, or that the pH buffer and at least one of the complexing agents are the same. The preceeding methodology can be advantageously utilized to determine other agents capable of complexing free calcium which can be added to the diluent for the analysis of clinical samples. EXAMPLES The following examples are presented for illustration purposes only and are not intended to limit the scope of the invention, the disclosure, or the claims that follow. Analysis of various diluents for the determination of total calcium was performed on a modified SYNCHRON ® EL-ISE™ analyzer (Beckman Instruments, Inc., Brea, CA. ) , utilizing a calcium-specific ion selective electrode similar to that described in Reference 1, infra. Serum samples from healthy individuals were diluted one part sample volume to twenty parts diluent; dilution was automatically accomplished by the aforementioned analyzer prior to analysis. All chemicals used for testing were ACS grade, and were freshly prepared prior to analysis. Calcium standards were prepared from a stock solution including therein SRM 915™ calcium carbonate. Example I Protein Effect on Calcium Recovery The aforementioned serum pools were spiked with 5.0 g/dl Human Serum Albumin (Cohn Fraction V, Sigma Chemical Co., St. Louis, MO.) for analysis of protein effect on calcium recovery. Differing amounts of the aforementioned calcium carbonate were added to the protein spiked serum samples. Comparisons were made between two diluents similar to that set forth as an embodiment of the diluent: the first included as a complexing agent only 0.15M phosphoric acid ("PA") and the second including both 0.15M phosphoric acid and 5 mmol citric acid ( "PA/CA" ) . Normalized calcium recovery results (normalized against the calcium recovery values in the absence of HSA) derived from the indirect potentiometric analysis of the samples are presented in Table I: TABLE I Normalized Calcium Recovery Diluent Agent Ca + + (mg/dl) PA PA/CA 5 .8667 1.0185 10 .8713 0.9907 15 .8782 0.9811 The results indicate that calcium recovery is significantly improved with the addition of citrate in the diluent. EXAMPLE II Citrate Effect on Calcium Recovery Reference 1,infra, describes a 30% reduction in the recovery of total calcium with the presence of 1 mmol of citrate in serum samples. Increasing amounts of citrate were added to serum samples and the aforementioned diluents of Example I were tested. Normalized calcium recovery values are set forth in Table II: TABLE II Normalized Calcium Recovery Diluent Agent Citrate (mmol) PA PA/CA 0 1.00 1.00 1.0 1.00 1.00 5.0 .97 .99 10.0 .93 .97 The results set forth in Table II indicate that at the 1.0 mmol citrate level, complete calcium recovery was obtained when either of the tested diluents were utilized. However, at the 5.0 mmol citrate level, the citrate effect on calcium recovery was approximately 3% when only phosphoric acid was used as the complexing agent, while the citrate effect was signficantly decreased when both phosphoric acid and citric acid were used as complexing agents. At the 10.0 mmol level, the citrate effect on calcium recovery was reduced by over 50% when both complexing agents were added to the diluent, compared to when only the phosphoric acid was added to the diluent. EXAMPLE III Correlation Study Serum correlation studies were conducted between the indirect potentiometric analysis for total calcium recovery and the atomic absorption method for calcium recovery, using a Jerrel Ash Model 12E™ AA Spectrophotmeter. For the indirect potentiometric analysis, the diluent included both of the aforementioned agents, phosphoric acid and citric acid. Correlation results summarized as follows: indirect = l ' 03 59 * X AA " °- 3302 N = 97 R 2 = .9844 EXAMPLE IV Determination of Calcium Concentration Dilution of a clinical sample can effectively place the diluted sample-calcium concentration into the non-linear range of the calcium-specific ion selective electrode. As such, the diluent preferably includes therein calcium or a salt thereof in an amount effective to correct for a decrease in sensitivity of a calcium-specific ion selective electrode. This additional calcium or calcium salt is referred to as a "spiking factor" or "SF". Generally, and because of the objective thereof, the concentration of the SF added to the sample is relatively small, usually on the order of from about 0.015 mmol/L of diluent to about 0.035mml/L of diluent, and most preferably, about 0.02 mmol of calcium carbonate is added per liter of diluent. When the diluent incorporates the SF therein, determination of calcium concentration in the clinical sample can be determined using the following modified Nicolskii-Eisenman equation: C Ca = antilog [(E Ca - E°)/S] - SF (5) where: E j -. a is the value (in mV) of the calcium-specific ion selective electrode towards the calcium in the diluted sample; E° is a constant EMF difference (temperature dependent); S is the slope and the electrical response function; SF is the value of the amount of the spiking factor added to the diluent as well as a system "carry-over" value attributed to residual calcium which may remain on the calcium specific ion selective electrode or flow cell; and C Ca is the determined concentration of calcium in the clinical sample. If a SF is not utilized in the diluent, then the concentration of calcium in the clinical sample can be determined as follows: C r - = antiglog [(E P C a a - E°)/S] ( 6) where the foregoing definitions apply. For a preferred analysis of clinical samples for the determination of calcium therein, an automatic electrolyte system utilizing an indirect potentiometric methodology can be utilized, such as, for example, a SYNCHRON ® EL-ISE™ analyzer (Beckman Instruments, Inc., Brea, CA.) although the invention is not to be limited in its applicability to this preferred analyzer. Most preferably, a 50ul clinical sample (e.g. serum) is diluted 20 fold with the most preferred diluent. For the analysis of the diluted sample, the aforementioned analyzer measures the calcium-specific ion selective electrode response this value is represented as E ( -. a . Equations 5 or 6 can then be utilized to determine the value for C Ca . The results from Examples I to IV establish the advantages derived from utilization of at least two calcium complexing agents in a diluent for use in the indirect potentiometric analysis of clinical samples for the determination of total calcium. The above examples are of preferred embodiments of the disclosed invention. Modifications that are within the purview of those skilled in the art are intended to be within the scope of the invention. BIBLIOGRAPHY 1. Anker, P. et al. "Neutral Carrier Based Ion- Selective Electrode for the Determination of Total Calcium in Blood Serum." Anal. Chem. 53:1970-1974 (1981) . 2. Gawoski, J.M. and Walsh, D. "Citrate Interference in Assays of Total Calcium in Serum." Clin. Chem. 35:2140-2141 (1989) 3. U.S. Patent No. 4,724,216 4. U.S. Patent No. 3,934,977 5. U.S. Patent No. 4,363,633 6. U.S. Patent No. 4,870,024

Claims: CLAIMS What is claimed is: 1. A diluent for the indirect potentiometric measurement of calcium in a clinical sample comprising, in effective amounts: a) a pH buffer; and b) at least two different agents capable of complexing free calcium in said sample, said agent-calcium complex association constants each having a range of from about 1.5 to about 7.0. 2. The diluent of Claim 1 wherein the pH buffer and at least one of the complexing agents are the same ingredient. 3. The diluent of Claim 2 wherein said ingredient is phosphoric acid having molar concentrations of phosphate[monobasic] and phosphate[dibasic] that are substantially the same. 4. The diluent of Claim 3 further including therein an effective amount of a counter cation. 5. The diluent of Claim 4 wherein said counter cation is tris(hydroxymethylJaminomethane. 6. The diluent of Claim 5 wherein the concentration of said phosphoric acid in said diluent is about 0.15 mole per liter and the concentration of said tris(hydroxymethyl) aminomethane in said diluent is about 0.30 mole per liter. 7. The diluent of Claim 1 wherein the pH range of said diluent is between about 5.0 and about 8.5. 8. The diluent of Claim 1 wherein the pH buffer is selected from the group consisting of acetic acid; 2-(N- morpholino)ethanesulfonic acid; 3-(N-morpholino) propanesulfonic acid; N-2-hydroxyethyl piperazine-N'-2- ethanesulfonic acid; phosphoric acid; N-[tris- (hydroxymethyl )methyljglycine; diethynol amine; dimethylamine; and the alkyl amines. 9. The diluent of Claim 1 wherein the association constant values of said agent-calcium complexes are each between about 2.0 and about 4.0. 10. The diluent of Claim 1 wherein said complexing agents are selected from the group consisting of: dicarboxylic acids; tricarboxyic acids; iminodiacetic acids; sulfonic acids; and organophosphoric acids. 11. The diluent of Claim 1 wherein said complexing agents are selected from the group consisting of: aspartic acid; gluconic acid; succinic acid; oxaloacetic acid; propane-l,2,3-tricarboxylic acid; citric acid; iminodiacetic acid; N-methyliminodiocetic acid; 4,5-dihydroxy-l,3- benzenedisulfonic acid; glycerol-2-phosphate, disodium salt; N-(-2-hydroxycyclohexyl) iminodiacetic acid; nitrilotriacetic acid; N'-( 2-hydroxyethyl) ethylenediamine- N,N,N'-triacetic acid; ethylenediamine-N, N-diacetic acid; 8-hydroxyquinoline-5-sulfonic acid; and phosphoric acid (dibasic) . 12. The diluent of Claim 1 wherein said complexing agents are phosphoric acid and citric acid. 13. The diluent of Claim 1 wherein the concentration of said pH buffer in said diluent is at least about 0.1 mole per liter. 14. The diluent of Claim 1 wherein the concentration of said pH buffer in said diluent is between about 0.1 mole per liter and about 0.4 mole per liter. 15. The diluent of Claim 14 wherein the concentration of said phosphoric acid in said diluent is about 0.15 mole per liter and the concentration of said citric acid in said diluent is about 0.005 mole per liter. 16. The diluent of Claim 1 wherein said pH buffer is phosphoric acid, said phosphoric acid comprising molar concentrations of phosphate[monobasic] and phosphate[dibasic] that are substantially the same. 17. A diluent for the indirect potentiometric measurement of calcium in a clinical sample, said diluent comprising, in effective amounts: a) phosphoric acid; and c) citric acid wherein the pH of said diluent is between about 5.0 to about 8.5. 18. The diluent of Claim 17 wherein the concentration of phosphoric acid in the diluent is about 0.15 mole per liter and the concentration of citric acid in the diluent is at least about 0.005 mole per liter. 19. A method for determining the concentration of total calcium in a clinical sample comprising the steps of: a) admixing said sample with a diluent to form a diluted sample, said diluent comprising: i) a pH buffer; and ii) at least two different agents capable of complexing free calcium in said sample, said agent-calcium complex association constants having a range of from about 1.5 to about 7.0; wherein the pH of said diluent is within the range of about 5.0 to about 8.5; b) contacting an aliquot of said diluted sample with a calcium specific ion selective; and c) measuring the response of said calcium specific ion selective electrode as an indication of the concentration of total calcium in said sample. 20. The method of Claim 19 wherein the volume to volume ratio of said sample to said diluent is between about 1:10 and about 1:40. 21. The method of Claim 19 wherein the volume to volume ratio of said sample to said diluent is about 1:20.

Inventors: SHU FRANK R, SHU, FRANK, R.
Applicants: BECKMAN INSTRUMENTS INC, BECKMAN INSTRUMENTS, INC.
Application year: 1991
Main classification: G01N33
IPC codes: G01N27, G01N33